Odonate, Inc.
US ˙ OTCPK ˙ US6760792050

Introduction

This page provides a comprehensive analysis of the known insider trading history of Davis Aaron I.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Davis Aaron I. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TNGX / Tango Therapeutics, Inc. 3,610,642
US:ITOS / iTeos Therapeutics, Inc. Director 2,946,915
US:TYRA / Tyra Biosciences, Inc. 85,939
Director 0
US:MRTX / Mirati Therapeutics, Inc. 0
US:ODT / Odonate Therapeutics Inc Director, 10% Owner 4,607,086
US:PMVP / PMV Pharmaceuticals, Inc. 0
10% Owner 0
US:ARDM / Aradigm Corp. 10% Owner 51,512,735
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Davis Aaron I.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ODTC / Odonate, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ODTC / Odonate, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-12-29 ODT Davis Aaron I. 225,000 17.1091 225,000 17.1091 3,849,548 41 27.39 2,313,203 60.09

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ODTC / Odonate, Inc. Insider Trades
Insider Sales ODTC / Odonate, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ODTC / Odonate, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-11-19 ODT Davis Aaron I. 30,000 1.9165 30,000 1.9165 57,495 49 1.0900 -24,795 -43.13
2021-11-17 ODT Davis Aaron I. 170,000 2.2334 170,000 2.2334 379,678

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ODTC / Odonate, Inc. Insider Trades
Insider Purchases PMVP / PMV Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ODTC / Odonate, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-09-25 PMVP Boxer Capital, LLC 950,000 18.0000 950,000 18.0000 17,100,000 97 61.51 41,334,500 241.72

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PMVP / PMV Pharmaceuticals, Inc. Insider Trades
Insider Sales PMVP / PMV Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ODTC / Odonate, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PMVP / PMV Pharmaceuticals, Inc. Insider Trades
Insider Purchases TNGX / Tango Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ODTC / Odonate, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-10-16 TNGX Boxer Capital, LLC 500,000 6.8400 500,000 6.8400 3,420,000 109 12.8800 3,020,000 88.30
2023-10-13 TNGX Boxer Capital, LLC 750,000 7.0700 750,000 7.0700 5,302,500
2023-08-11 TNGX Boxer Capital, LLC 475,000 5.1500 475,000 5.1500 2,446,250
2022-10-13 TNGX Boxer Capital, LLC 70,000 4.6461 70,000 4.6461 325,227
2022-10-12 TNGX Boxer Capital, LLC 50,000 4.4328 50,000 4.4328 221,640
2022-10-11 TNGX Boxer Capital, LLC 117,000 4.2539 117,000 4.2539 497,706

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNGX / Tango Therapeutics, Inc. Insider Trades
Insider Sales TNGX / Tango Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ODTC / Odonate, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-11-06 TNGX Boxer Capital Management, LLC 3,080,000 3.1400 3,080,000 3.1400 9,671,200 183 1.1000 -6,283,200 -64.97
2024-10-25 TNGX Boxer Capital Management, LLC 633,000 6.8700 633,000 6.8700 4,348,710
2024-10-22 TNGX Boxer Capital Management, LLC 250,000 6.7800 250,000 6.7800 1,695,000
2024-10-21 TNGX Boxer Capital Management, LLC 625,000 7.0500 625,000 7.0500 4,406,250
2024-07-02 TNGX MVA Investors, LLC 95,000 8.6800 95,000 8.6800 824,600
2024-07-01 TNGX MVA Investors, LLC 110,731 8.8700 110,731 8.8700 982,184
2024-06-28 TNGX MVA Investors, LLC 29,000 8.5700 29,000 8.5700 248,530
2024-06-07 TNGX MVA Investors, LLC 77,000 6.8800 77,000 6.8800 529,760
2024-06-06 TNGX MVA Investors, LLC 63,000 7.2400 63,000 7.2400 456,120
2024-05-03 TNGX MVA Investors, LLC 60,000 7.6100 60,000 7.6100 456,600
2024-05-02 TNGX MVA Investors, LLC 75,000 7.5600 75,000 7.5600 567,000
2024-05-01 TNGX MVA Investors, LLC 75,000 7.4300 75,000 7.4300 557,250
2023-10-09 TNGX Boxer Capital, LLC 50,000 9.9100 50,000 9.9100 495,500
2023-10-09 TNGX Boxer Capital, LLC 175,000 9.9700 175,000 9.9700 1,744,750

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TNGX / Tango Therapeutics, Inc. Insider Trades
Insider Purchases TYRA / Tyra Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ODTC / Odonate, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-09-17 TYRA Boxer Capital, LLC 625,000 16.0000 625,000 16.0000 10,000,000 48 31.3500 9,593,750 95.94

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TYRA / Tyra Biosciences, Inc. Insider Trades
Insider Sales TYRA / Tyra Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ODTC / Odonate, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-02-10 TYRA MVA Investors, LLC 65,568 13.4000 65,568 13.4000 878,611 13 10.2600 -205,883 -23.43
2023-02-09 TYRA MVA Investors, LLC 200,000 13.1000 200,000 13.1000 2,620,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TYRA / Tyra Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Davis Aaron I. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-11-07 2024-11-06 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -3,080,000 3,610,642 -46.03 3.14 -9,671,200 11,337,416
2024-10-28 2024-10-25 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -633,000 6,690,642 -8.64 6.87 -4,348,710 45,964,711
2024-10-23 2024-10-22 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -250,000 7,323,642 -3.30 6.78 -1,695,000 49,654,293
2024-10-23 2024-10-21 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -625,000 7,573,642 -7.62 7.05 -4,406,250 53,394,176
2024-07-02 2024-07-02 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -95,000 108,793 -46.62 8.68 -824,600 944,323
2024-07-02 2024-07-01 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -110,731 203,793 -35.21 8.87 -982,184 1,807,644
2024-07-02 2024-06-28 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -29,000 314,524 -8.44 8.57 -248,530 2,695,471
2024-06-07 2024-06-07 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -77,000 343,524 -18.31 6.88 -529,760 2,363,445
2024-06-07 2024-06-06 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -63,000 420,524 -13.03 7.24 -456,120 3,044,594
2024-05-14 2024-05-10 4 ITOS iTeos Therapeutics, Inc.
Common Stock
A - Award 1,142,857 2,946,915 63.35 17.50 19,999,998 51,571,012
2024-05-03 2024-05-03 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -60,000 483,524 -11.04 7.61 -456,600 3,679,618
2024-05-03 2024-05-02 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -75,000 543,524 -12.13 7.56 -567,000 4,109,041
2024-05-03 2024-05-01 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -75,000 618,524 -10.81 7.43 -557,250 4,595,633
2024-02-08 2024-02-06 4 TYRA Tyra Biosciences, Inc.
Common Stock
A - Award 63,412 85,939 281.49 13.01 824,990 1,118,066
2024-01-26 2024-01-26 4 RAIN Rain Oncology Inc.
Common Stock, par value $0.001 per share
U - Other -79,726 0 -100.00
2024-01-25 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -30,518 0 -100.00
2024-01-25 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -3,135,966 0 -100.00
2024-01-25 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -203,754 0 -100.00
2024-01-25 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -3,201,440 0 -100.00
2024-01-25 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -287,866 0 -100.00
2024-01-23 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -6,808 0 -100.00
2024-01-23 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -4,444 6,808 -39.50
2024-01-23 2024-01-23 4 MRTX Mirati Therapeutics, Inc.
Common Stock
D - Sale to Issuer -43,073 11,252 -79.29
2024-01-03 2023-12-29 4 MRTX Mirati Therapeutics, Inc.
Common Stock
A - Award 6,808 54,325 14.33 58.75 399,970 3,191,594
2023-10-17 2023-10-16 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 500,000 8,198,642 6.49 6.84 3,420,000 56,078,711
2023-10-17 2023-10-13 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 750,000 7,698,642 10.79 7.07 5,302,500 54,429,399
2023-10-17 2023-10-16 4/A TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 500,000 8,198,642 6.49 6.84 3,420,000 56,078,711
2023-10-17 2023-10-13 4/A TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 750,000 7,698,642 10.79 7.07 5,302,500 54,429,399
2023-10-11 2023-08-11 4/A TNGX Tango Therapeutics, Inc.
Common Stock
A - Award 475,000 743,542 176.88 5.15 2,446,250 3,829,241
2023-10-11 2023-10-09 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -175,000 6,948,642 -2.46 9.97 -1,744,750 69,277,961
2023-10-11 2023-10-09 4 TNGX Tango Therapeutics, Inc.
Common Stock
S - Sale -50,000 693,524 -6.72 9.91 -495,500 6,872,823
2023-08-25 2023-08-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -219,638 1,804,058 -10.85 16.87 -3,705,293 30,434,458
2023-08-25 2023-08-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -95,516 2,023,696 -4.51 15.63 -1,492,915 31,630,368
2023-08-25 2023-08-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -34,846 2,119,212 -1.62 14.19 -494,465 30,071,618
2023-08-15 2023-08-11 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 475,000 743,542 176.88 5.15 2,446,250 3,829,241
2023-08-15 2023-08-11 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 1,201,440 3,201,440 60.07 27.80 33,400,032 89,000,032
2023-08-15 2023-08-11 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 57,533 287,866 24.98 27.80 1,599,417 8,002,675
2023-08-15 2023-08-11 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 1,201,440 3,201,440 60.07 27.80 33,400,032 89,000,032
2023-08-15 2023-08-11 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 57,533 287,866 24.98 27.80 1,599,417 8,002,675
2023-06-08 2023-06-06 4 TNGX Tango Therapeutics, Inc.
Common Stock
A - Award 5,000 5,000
2023-05-24 2023-05-22 4 RAIN Rain Oncology Inc.
Common Stock
S - Sale -995,000 1,152,212 -46.34 1.25 -1,243,750 1,440,265
2023-02-13 2023-02-10 4 TYRA Tyra Biosciences, Inc.
Common Stock
S - Sale -65,568 22,527 -74.43 13.40 -878,611 301,862
2023-02-13 2023-02-09 4 TYRA Tyra Biosciences, Inc.
Common Stock
S - Sale -200,000 88,095 -69.42 13.10 -2,620,000 1,154,044
2023-01-24 2023-01-20 4 MRTX Mirati Therapeutics, Inc.
Common Stock
A - Award 4,444 47,517 10.32
2022-11-08 2022-11-04 4 RAIN Rain Therapeutics Inc.
Common Stock
P - Purchase 972,212 2,147,212 82.74 5.83 5,667,996 12,518,246
2022-10-13 2022-10-13 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 70,000 7,123,642 0.99 4.65 325,227 33,097,153
2022-10-13 2022-10-12 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 50,000 268,524 22.88 4.43 221,640 1,190,313
2022-10-13 2022-10-11 4 TNGX Tango Therapeutics, Inc.
Common Stock
P - Purchase 117,000 218,524 115.24 4.25 497,706 929,579
2022-05-11 2022-05-11 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -337,109 2,154,058 -13.53 18.25 -6,151,801 39,308,758
2022-05-11 2022-05-11 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -891 2,491,167 -0.04 17.53 -15,621 43,675,140
2022-05-11 2022-05-10 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -4,850 2,492,058 -0.19 24.77 -120,112 61,716,564
2022-05-11 2022-05-10 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -95,150 2,496,908 -3.67 25.18 -2,395,858 62,871,644
2022-05-11 2022-05-09 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -200,000 2,592,058 -7.16 23.47 -4,693,120 60,824,196
2022-05-11 2022-05-09 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -25,000 2,792,058 -0.89 22.91 -572,722 63,962,978
2022-05-02 2022-05-02 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -92,700 2,817,058 -3.19 27.53 -2,552,328 77,562,621
2022-05-02 2022-05-02 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -7,300 2,909,758 -0.25 26.90 -196,406 78,287,039
2022-05-02 2022-04-29 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -115,000 2,917,058 -3.79 27.01 -3,106,668 78,802,863
2022-05-02 2022-04-29 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -10,000 3,032,058 -0.33 28.22 -282,154 85,550,729
2022-05-02 2022-04-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -150,000 3,042,058 -4.70 27.40 -4,110,315 83,358,778
2022-03-24 2022-03-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 20,000 3,192,058 0.63 32.85 656,980 104,855,913
2022-03-24 2022-03-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 5,000 3,172,058 0.16 33.43 167,139 106,034,920
2022-03-24 2022-03-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 3,700 3,167,058 0.12 33.09 122,432 104,797,316
2022-03-24 2022-03-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 21,300 3,163,358 0.68 31.88 678,938 100,832,036
2022-01-18 2022-01-14 4 MRTX Mirati Therapeutics, Inc.
Non Qualified Stock Option (right to buy)
A - Award 3,688 3,688
2022-01-18 2022-01-14 4 MRTX Mirati Therapeutics, Inc.
Common Stock
A - Award 2,546 43,073 6.28
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -2,517 0 -100.00 45.48 -114,467
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -11,199 2,517 -81.65 44.44 -497,701 111,860
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -3,138 13,716 -18.62 43.36 -136,062 594,720
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -29,623 16,854 -63.74 41.84 -1,239,486 705,205
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -7,483 3,717,259 -0.20 45.48 -340,310 169,052,390
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -33,297 3,724,742 -0.89 44.44 -1,479,772 165,533,494
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -9,366 3,758,039 -0.25 43.36 -406,110 162,948,571
2022-01-05 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -88,054 3,767,405 -2.28 41.84 -3,684,355 157,635,760
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -731 46,477 -1.55 50.63 -37,013 2,353,307
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -1,682 47,208 -3.44 49.37 -83,049 2,330,890
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -23,353 48,890 -32.33 47.63 -1,112,245 2,328,508
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -17,173 3,855,459 -0.44 50.63 -869,534 195,216,540
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -39,481 3,872,632 -1.01 49.37 -1,949,355 191,209,269
2022-01-05 2022-01-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -432,903 3,912,113 -9.96 47.65 -20,626,183 186,397,318
2021-11-19 2021-11-19 4 ODT Odonate Therapeutics, Inc.
Common Stock
S - Sale -150,000 4,607,086 -3.15 1.84 -276,285 8,485,792
2021-11-19 2021-11-19 4 ODT Odonate Therapeutics, Inc.
Common Stock
S - Sale -30,000 445,756 -6.31 1.92 -57,495 854,291
2021-11-19 2021-11-18 4 ODT Odonate Therapeutics, Inc.
Common Stock
S - Sale -250,000 4,757,086 -4.99 1.95 -487,250 9,271,561
2021-11-19 2021-11-17 4 ODT Odonate Therapeutics, Inc.
Common Stock
S - Sale -600,000 5,007,086 -10.70 2.17 -1,299,240 10,842,344
2021-11-19 2021-11-17 4 ODT Odonate Therapeutics, Inc.
Common Stock
S - Sale -170,000 475,756 -26.33 2.23 -379,678 1,062,553
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Series B Preferred Stock
C - Conversion -15,401 0 -100.00
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Series B Preferred Stock
C - Conversion -713,629 0 -100.00
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Series A Preferred Stock
C - Conversion -95,516 0 -100.00
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Series A Preferred Stock
C - Conversion -1,480,242 0 -100.00
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Common Stock
C - Conversion 288,095 288,095
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Common Stock
P - Purchase 625,000 6,323,359 10.97 16.00 10,000,000 101,173,744
2021-09-17 2021-09-17 4 TYRA Tyra Biosciences, Inc.
Common Stock
C - Conversion 5,698,359 5,698,359
2021-06-21 2021-06-17 4 ITOS iTeos Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,608 16,608
2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock
C - Conversion 79,726 79,726
2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock
C - Conversion 3,022,489 3,022,489
2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Series B Preferred Stock
C - Conversion -86,097 0 -100.00
2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Series B Preferred Stock
C - Conversion -3,263,986 0 -100.00
2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Common Stock
P - Purchase 1,025,000 1,175,000 683.33 17.00 17,425,000 19,975,000
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock
P - Purchase 125,000 150,000 500.00 16.27 2,033,750 2,440,500
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock
P - Purchase 25,000 25,000 15.58 389,500 389,500
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
M - Exercise -468,639 332,809 -58.47 13.00 -6,091,838 4,326,184
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
M - Exercise -128,805 0 -100.00 5.60 -721,179
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
M - Exercise -13,996 0 -100.00 5.60 -78,364
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -363,000 2,000,000 -15.36 181.15 -65,757,450 362,300,000
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -4 2,363,000 0.00 181.00 -724 427,703,000
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
M - Exercise 597,444 2,363,004 33.84 0.00 597 2,363
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -37,000 230,333 -13.84 181.15 -6,702,550 41,724,823
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -1 267,333 0.00 181.00 -181 48,387,273
2021-03-09 2021-03-05 4 MRTX Mirati Therapeutics, Inc.
Common Stock
M - Exercise 13,996 267,334 5.52 0.00 14 267
2021-01-20 2021-01-15 4 MRTX Mirati Therapeutics, Inc.
Non Qualified Stock Option (right to buy)
A - Award 2,155 2,155
2021-01-20 2021-01-15 4 MRTX Mirati Therapeutics, Inc.
Common Stock
A - Award 1,475 40,527 3.78
2020-12-30 2020-12-30 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 100,000 5,607,086 1.82 17.46 1,746,380 97,921,028
2020-12-30 2020-12-29 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 225,000 5,507,086 4.26 17.11 3,849,548 94,221,285
2020-12-30 2020-12-28 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 75,000 5,282,086 1.44 16.90 1,267,500 89,267,253
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
M - Exercise -37,051 13,996 -72.58 5.60 -207,449 78,364
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
M - Exercise -362,952 128,805 -73.81 5.60 -2,032,168 721,179
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
F - Taxes -2 1,765,560 0.00 219.97 -440 388,370,233
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
M - Exercise 362,952 1,765,562 25.88 0.00 363 1,766
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -362,950 1,404,610 -20.53 202.00 -73,315,900 283,731,220
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
F - Taxes -1 253,338 0.00 219.97 -220 55,726,760
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
M - Exercise 37,051 253,339 17.13 0.00 37 253
2020-10-30 2020-10-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -37,050 216,288 -14.62 202.00 -7,484,100 43,690,176
2020-10-21 2020-07-23 4/A ITOS iTeos Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,608 0 -100.00
2020-09-30 2020-09-29 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 122,000 5,207,086 2.40 14.08 1,717,760 73,315,771
2020-09-30 2020-09-28 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 93,200 5,085,086 1.87 13.03 1,214,396 66,258,671
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series D Preferred Stock
C - Conversion -28,129 0 -100.00
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series D Preferred Stock
C - Conversion -732,137 0 -100.00
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series C Preferred Stock
C - Conversion -32,708 0 -100.00
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series C Preferred Stock
C - Conversion -586,099 0 -100.00
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock
C - Conversion 28,129 60,837 86.00
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock
C - Conversion 32,708 32,708
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock
C - Conversion 732,137 2,268,236 47.66
2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock
C - Conversion 586,099 1,536,099 61.69
2020-09-29 2020-09-25 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock
P - Purchase 950,000 950,000 18.00 17,100,000 17,100,000
2020-09-09 2020-09-09 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 81,100 4,991,886 1.65 15.20 1,232,720 75,876,667
2020-09-09 2020-09-08 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 18,800 4,910,786 0.38 14.69 276,172 72,139,446
2020-09-09 2020-09-04 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 125,100 4,891,986 2.62 14.89 1,862,739 72,841,672
2020-09-01 2020-08-28 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 1,403,509 4,766,886 41.73 14.25 20,000,003 67,928,126
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -158,687 0 -100.00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -9,593,086 0 -100.00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 23,552 72,243 48.37 19.00 447,488 1,372,617
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 1,401,448 4,345,016 47.61 19.00 26,627,512 82,555,304
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 48,691 48,691
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 2,943,568 2,943,568
2020-07-24 2020-07-23 4 ITOS iTeos Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,608 0 -100.00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -120,460 0 -100.00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -7,064,136 0 -100.00
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
P - Purchase 722,222 2,107,513 52.14 18.00 12,999,996 37,935,234
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 23,622 23,622
2020-07-21 2020-07-21 4 PAND Pandion Therapeutics, Inc.
Common Stock
C - Conversion 1,385,291 1,385,291
2020-01-07 2020-01-03 4 MRTX Mirati Therapeutics, Inc.
Non Qualified Stock Option (right to buy)
A - Award 4,000 4,000
2020-01-07 2020-01-03 4 MRTX Mirati Therapeutics, Inc.
Common Stock
A - Award 2,000 39,052 5.40
2019-01-22 2019-01-17 4 MRTX Mirati Therapeutics, Inc.
Non-Qualified Stock Option (right to buy)
A - Award 11,000 11,000
2019-01-09 2019-01-08 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -5,000 37,052 -11.89 53.40 -267,000 1,978,577
2019-01-09 2019-01-08 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -5,000 42,052 -10.63 52.20 -261,000 2,195,114
2019-01-09 2019-01-07 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -15,000 47,052 -24.17 47.48 -712,200 2,234,029
2019-01-09 2019-01-07 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -8,357 62,052 -11.87 46.29 -386,846 2,872,387
2019-01-09 2019-01-07 4 MRTX Mirati Therapeutics, Inc.
Common Stock
S - Sale -16,643 70,409 -19.12 45.47 -756,757 3,201,497
2018-12-27 2018-12-26 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 25,000 2,978,762 0.85 12.47 311,815 37,152,907
2018-12-27 2018-12-21 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 75,000 2,953,762 2.61 13.47 1,010,602 39,801,057
2018-12-27 2018-12-21 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 25,000 2,878,762 0.88 13.46 336,412 38,738,061
2018-12-10 2018-12-06 4 MRTX Mirati Therapeutics, Inc.
Non-Qualified Stock Option (right to buy)
A - Award 25,000 25,000
2018-10-26 2018-10-24 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 26,824 2,853,762 0.95 14.72 394,753 41,997,103
2018-03-26 2018-03-26 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 33,650 2,826,938 1.20 22.41 754,096 63,351,681
2018-03-26 2018-03-23 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 42,943 2,793,288 1.56 23.96 1,028,914 66,927,180
2018-03-26 2018-03-22 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 23,407 2,750,345 0.86 20.94 490,143 57,592,224
2017-12-08 2017-12-06 4 ODT Odonate Therapeutics, Inc.
Common Stock
P - Purchase 416,666 2,726,938 18.04 24.00 9,999,984 65,446,512
2017-12-06 3 ODT Odonate Therapeutics, LLC
Common Stock
3,601,784
2017-12-06 3 ODT Odonate Therapeutics, LLC
Common Stock
5,266,300
2017-12-06 3 ODT Odonate Therapeutics, LLC
Common Stock
3,601,784
2017-12-06 3 ODT Odonate Therapeutics, LLC
Common Stock
5,266,300
2017-10-03 2017-10-03 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
X - Other -78,186 0 -100.00
2017-10-03 2017-10-03 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
X - Other -189,780 0 -100.00
2017-10-03 2017-10-03 4 MRTX Mirati Therapeutics, Inc.
Common Stock
X - Other 78,186 513,630 17.96 7.86 614,542 4,037,132
2017-10-03 2017-10-03 4 MRTX Mirati Therapeutics, Inc.
Common Stock
X - Other 189,780 1,227,774 18.28 7.86 1,491,671 9,650,304
2017-01-10 2017-01-06 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
P - Purchase 51,047 51,047 5.60 285,812 285,812
2017-01-10 2017-01-06 4 MRTX Mirati Therapeutics, Inc.
Warrant (right to purchase)
P - Purchase 2,341,786 2,341,786 5.60 13,111,660 13,111,660
2017-01-10 2017-01-06 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 6,104 435,444 1.42 5.60 34,182 2,438,486
2017-01-10 2017-01-06 4 MRTX Mirati Therapeutics, Inc.
Common Stock
P - Purchase 280,059 1,037,994 36.95 5.60 1,568,330 5,812,766
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
1,770,293
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
2,947,956
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
2,145,203
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
1,770,293
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
2,947,956
2016-01-15 3 MRTX Mirati Therapeutics, Inc.
Common Stock
2,145,203
2013-05-30 3 ARDM ARADIGM CORP
Common Stock
51,512,735
2013-05-30 3 ARDM ARADIGM CORP
Common Stock
51,512,735
2013-05-30 3 ARDM ARADIGM CORP
Common Stock
2,890,625
2013-05-30 3 ARDM ARADIGM CORP
Common Stock
450,300
2013-05-30 3 ARDM ARADIGM CORP
Common Stock
2,664,254
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)